RVXOT - If RVX were presently operating in the normal course of business then yes, I agree with you.  But I also agree with CCDude that at this stage, with topline less than 2 months away, it’s all about the science.  Sure, they still have to manage their cash, continue working closely with Third Eye, comply with loan covenants, etc.  That’s just an ongoing part of management’s job and they’ll get it done if it isn’t done already, which i suspect it probably is.  Besides, in the big scheme of things (in terms of monies already invested in Apabetalone to date) these loans are peanuts, and even more so if topline is positive.

If topline is negative there has to be enough money to keep things going until the full data release, and one way or another those funds will be there, 100% guaranteed, because no major shareholder is going to bail until all that information is available. In for a penny in for a pound.  However, if those results also fail to show any promise, or at a minimum any substantive hint of promise, then yes..... na na na na hey hey goodbye.  But, I don’t think that will happen.  As I’ve said before, given the number of years of research invested in this drug there are just too many possible outcomes for them to miss on all of them.  Possible yes, likely no.  So, we continue to wait and hope the result will be worth the price of admission.